The Relevance of Biologically Effective Dose for Hearing Preservation After Stereotactic Radiosurgery for Vestibular Schwannomas: A Retrospective Longitudinal Study.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
01 06 2023
Historique:
received: 08 08 2022
accepted: 08 11 2022
pmc-release: 24 01 2024
medline: 17 5 2023
pubmed: 3 2 2023
entrez: 2 2 2023
Statut: ppublish

Résumé

Stereotactic radiosurgery has become a common treatment approach for small-to-medium size vestibular schwannomas. To evaluate relationship between time (beam-on and treatment) and risk of hearing decline after stereotactic radiosurgery for vestibular schwannomas in patients with Gardner-Robertson (GR) baseline classes I and II. This retrospective longitudinal single-center study included 213 patients with GR I and II treated between June 2010 and December 2019. Risk of passing from GR classes I and II (coded 0) to other classes III, IV, and V (coded 1) and the increase in pure tone average (continuous outcome) were evaluated using a mixed-effect regression model. Biologically effective dose (BED) was further assessed for an alpha/beta ratio of 2.47 (Gy 2.47 ). Binary outcome analysis revealed sex, dose rate, integral dose, time [beam-on time odds ratio 1.03, P = .03, 95% CI 1.00-1.06; treatment time ( P = .02) and BED ( P = .001) as relevant. Fitted multivariable model included the sex, dose rate, and BED. Pure tone average analysis revealed age, integral dose received by tumor, isocenter number, time (beam-on time odds ratio 0.20, P = .001, 95% CI 0.083-0.33) and BED ( P = .005) as relevant. Our analysis showed that risk of hearing decline was associated with male sex, higher radiation dose rate (cutoff 2.5 Gy/minute), higher integral dose received by the tumor, higher beam-on time ≥20 minutes, and lower BED. A BED between 55 and 61 was considered as optimal for hearing preservation.

Sections du résumé

BACKGROUND
Stereotactic radiosurgery has become a common treatment approach for small-to-medium size vestibular schwannomas.
OBJECTIVE
To evaluate relationship between time (beam-on and treatment) and risk of hearing decline after stereotactic radiosurgery for vestibular schwannomas in patients with Gardner-Robertson (GR) baseline classes I and II.
METHODS
This retrospective longitudinal single-center study included 213 patients with GR I and II treated between June 2010 and December 2019. Risk of passing from GR classes I and II (coded 0) to other classes III, IV, and V (coded 1) and the increase in pure tone average (continuous outcome) were evaluated using a mixed-effect regression model. Biologically effective dose (BED) was further assessed for an alpha/beta ratio of 2.47 (Gy 2.47 ).
RESULTS
Binary outcome analysis revealed sex, dose rate, integral dose, time [beam-on time odds ratio 1.03, P = .03, 95% CI 1.00-1.06; treatment time ( P = .02) and BED ( P = .001) as relevant. Fitted multivariable model included the sex, dose rate, and BED. Pure tone average analysis revealed age, integral dose received by tumor, isocenter number, time (beam-on time odds ratio 0.20, P = .001, 95% CI 0.083-0.33) and BED ( P = .005) as relevant.
CONCLUSION
Our analysis showed that risk of hearing decline was associated with male sex, higher radiation dose rate (cutoff 2.5 Gy/minute), higher integral dose received by the tumor, higher beam-on time ≥20 minutes, and lower BED. A BED between 55 and 61 was considered as optimal for hearing preservation.

Identifiants

pubmed: 36727756
doi: 10.1227/neu.0000000000002352
pii: 00006123-202306000-00014
pmc: PMC10150919
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1216-1226

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Congress of Neurological Surgeons.

Références

Carlson ML, Link MJ. Vestibular schwannomas. N Engl J Med. 2021;384(14):1335-1348.
Kondziolka D, Mousavi SH, Kano H, Flickinger JC, Lunsford LD. The newly diagnosed vestibular schwannoma: radiosurgery, resection, or observation? Neurosurg Focus. 2012;33(3):E8.
Reznitsky M, Petersen M, West N, Stangerup SE, Caye-Thomasen P. Epidemiology of vestibular schwannomas—prospective 40-year data from an unselected national cohort. Clin Epidemiol. 2019;11:981-986.
Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery. 1997;40(1):1-9; discussion 9-10.
Hadjipanayis CG, Carlson ML, Link MJ, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on surgical resection for the treatment of patients with vestibular schwannomas. Neurosurgery. 2018;82(2):E40-E43.
Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro Oncol. 2020;22(1):31-45.
Gauden A, Weir P, Hawthorne G, Kaye A. Systematic review of quality of life in the management of vestibular schwannoma. J Clin Neurosci. 2011;18(12):1573-1584.
Gurewitz J, Schnurman Z, Nakamura A, et al. Hearing loss and volumetric growth rate in untreated vestibular schwannoma. J Neurosurg. 2022;136(3):768-775.
Johnson S, Kano H, Faramand A, et al. Long term results of primary radiosurgery for vestibular schwannomas. J Neurooncol. 2019;145(2):247-255.
Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med. 1998;339(20):1426-1433.
Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg. 2005;102(suppl):195-199.
Ruess D, Pohlmann L, Grau S, et al. Outcome and toxicity analysis of single dose stereotactic radiosurgery in vestibular schwannoma based on the Koos grading system. Sci Rep. 2020;10(1):9309.
Yomo S, Carron R, Thomassin JM, Roche PH, Regis J. Longitudinal analysis of hearing before and after radiosurgery for vestibular schwannoma. J Neurosurg. 2012;117(5):877-885.
Tuleasca C, Regis J, Letter LevivierM. Treatment outcomes and dose rate effects following gamma knife stereotactic radiosurgery for vestibular schwannomas. Neurosurgery. 2020;86(2):E252-E253.
Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8(11):1981-1997.
Barendsen GW. Modification of radiation damage by fractionation of the dose, anoxia, and chemical protectors in relation to let. Ann N Y Acad Sci. 1964;114:96-114.
Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83(991):554-568.
Gardner G, Robertson JH. Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol. 1988;97(1):55-66.
House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93(2):146-147.
Erickson NJ, Schmalz PGR, Agee BS, et al. Koos classification of vestibular schwannomas: a reliability study. Neurosurgery. 2019;85(3):409-414.
Hayashi M, Chernov M, Tamura N, et al. Gamma knife robotic microradiosurgery for benign skull base meningiomas: tumor shrinkage may depend on the amount of radiation energy delivered per lesion volume (unit energy). Stereotact Funct Neurosurg. 2011;89(1):6-16.
Massager N, Nissim O, Delbrouck C, et al. Irradiation of cochlear structures during vestibular schwannoma radiosurgery and associated hearing outcome. J Neurosurg. 2007;107(4):733-739.
Tamura M, Carron R, Yomo S, et al. Hearing preservation after gamma knife radiosurgery for vestibular schwannomas presenting with high-level hearing. Neurosurgery. 2009;64(2):289-296; discussion 296.
Tuleasca C, George M, Faouzi M, et al. Acute clinical adverse radiation effects after Gamma Knife surgery for vestibular schwannomas. J Neurosurg. 2016;125(suppl 1):73-82.
Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys. 2004;59(1):242-249.
Jones B, Hopewell JW. Modelling the influence of treatment time on the biological effectiveness of single radiosurgery treatments: derivation of “protective” dose modification factors. Br J Radiol. 2019;92(1093):20180111.
Pop LA, Millar WT, van der Plas M, van der Kogel AJ. Radiation tolerance of rat spinal cord to pulsed dose rate (PDR-) brachytherapy: the impact of differences in temporal dose distribution. Radiother Oncol. 2000;55(3):301-315.
Dhere VR, Tian S, Buchwald Z, et al. Moderately hypofractionated radiation for benign meningiomas and schwannomas: a report of 70 patients treated between 2008 and 2018. Adv Radiat Oncol. 2020;5(6):1147-1151.
Henzel M, Gross MW, Hamm K, et al. Stereotactic radiotherapy of meningiomas: symptomatology, acute and late toxicity. Strahlenther Onkol. 2006;182(7):382-388.
Henzel M, Hamm K, Sitter H, et al. Comparison of stereotactic radiosurgery and fractionated stereotactic radiotherapy of acoustic neurinomas according to 3-D tumor volume shrinkage and quality of life. Strahlenther Onkol. 2009;185(9):567-573.
Linskey ME. Stereotactic radiosurgery versus stereotactic radiotherapy for patients with vestibular schwannoma: a Leksell Gamma Knife Society 2000 debate. J Neurosurg. 2000;93(suppl 3):90-95.
Shrieve DC, Hazard L, Boucher K, Jensen RL. Dose fractionation in stereotactic radiotherapy for parasellar meningiomas: radiobiological considerations of efficacy and optic nerve tolerance. J Neurosurg. 2004;101(suppl 3):390-395.
Berger A, Alzate JD, Bernstein K, et al. Modern hearing preservation outcomes after vestibular schwannoma stereotactic radiosurgery. Neurosurgery. 2022;91(4):648-657.
Lobato-Polo J, Kondziolka D, Zorro O, Kano H, Flickinger JC, Lunsford LD. Gamma knife radiosurgery in younger patients with vestibular schwannomas. Neurosurgery. 2009;65(2):294-300; discussion 300-301.
Johnson S, Kano H, Faramand A, Niranjan A, Flickinger JC, Lunsford LD. Predicting hearing outcomes before primary radiosurgery for vestibular schwannomas. J Neurosurg. Published online ahead of print September 6, 2019. DOI: 10.3171/2019.5.JNS182765.
doi: 10.3171/2019.5.JNS182765
Smith DR, Saadatmand HJ, Wu CC, et al. Treatment outcomes and dose rate effects following gamma knife stereotactic radiosurgery for vestibular schwannomas. Neurosurgery. 2019;85(6):E1084-E1094.
Cui T, Nie K, Zhu J, et al. Clinical evaluation of the inverse planning system utilized in Gamma knife lightning. Front Oncol. 2022;12:832656.

Auteurs

Constantin Tuleasca (C)

Neurosurgery Service and Gamma Knife Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Faculty of Biology and Medicine (FBM), University of Lausanne (UNIL), Switzerland.
Ecole Polytechnique Fédérale de Lausanne (EPFL, LTS-5), Lausanne, Switzerland.

Iuliana Toma-Dasu (I)

Oncology Pathology Department, Karolinska Institutet, Stockholm, Sweden.
Medical Radiation Physics, Stockholm University, Stockholm, Sweden.

Sebastien Duroux (S)

Faculty of Biology and Medicine (FBM), University of Lausanne (UNIL), Switzerland.

Daniele Starnoni (D)

Neurosurgery Service and Gamma Knife Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Faculty of Biology and Medicine (FBM), University of Lausanne (UNIL), Switzerland.

Mercy George (M)

ENT Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Raphael Maire (R)

ENT Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Roy Thomas Daniel (RT)

Neurosurgery Service and Gamma Knife Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Faculty of Biology and Medicine (FBM), University of Lausanne (UNIL), Switzerland.

David Patin (D)

Institute of Radiation Physics, Lausanne, Switzerland.

Luis Schiappacasse (L)

Radiation Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Alexandru Dasu (A)

The Skandion Clinic, Uppsala, Sweden.
Medical Radiation Sciences, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Mohamed Faouzi (M)

Division of Biostatistics, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland.

Marc Levivier (M)

Neurosurgery Service and Gamma Knife Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Faculty of Biology and Medicine (FBM), University of Lausanne (UNIL), Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH